Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Guidance Explains Upcoming Enhancements To Inactive Ingredients Database

Executive Summary

Next year, generic drug manufacturers will finally get some of the improvements they have been asking for in the US FDA’s Inactive Ingredient Database, such as being able to access the maximum daily intake (MDI) for each excipient. This information is helpful to industry in formulating products.

You may also be interested in...



US FDA Seeks Ability To Include More Inactive Ingredient, Excipient Info In Brand Labeling

Additions could help streamline generic development, Center for Drug Evaluation and Research Director Patrizia Cavazzoni says.

FDA Shifts On Measuring Daily Limits For Excipients From Potency To Maximum Exposure

International Pharmaceutical Excipients Council of the Americas supports the maximum daily exposure limit but suggests FDA retain potency limit field until it finishes adding MDE information to avoid causing confusion.

New Exposure Limits For Excipients Applauded

The US FDA has launched the second phase of an effort to improve its inactive ingredients database by replacing confusing potency amounts with maximum daily exposure limits, a change sought by generic drug and excipient manufacturers.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS125620

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel